Show simple item record

dc.contributor.authorWoof, V. G.
dc.contributor.authorLee, Rebecca J
dc.contributor.authorLorigan, Paul C
dc.contributor.authorFrench, DP
dc.date.accessioned2022-05-25T10:55:16Z
dc.date.available2022-05-25T10:55:16Z
dc.date.issued2022
dc.identifier.citationWoof, V. G, Lee, R J, Lorigan, P C, French, D Pen_US
dc.identifier.pmid35301436
dc.identifier.doi10.1038/s41416-022-01766-x
dc.identifier.urihttp://hdl.handle.net/10541/625201
dc.description.abstract"Background: Circulating tumour DNA (ctDNA) monitoring is a new technology that detects cancer DNA fragments in blood circulation. Regular monitoring with ctDNA has the potential to detect and treat cancer relapse earlier, but there is little evidence on patient acceptability. This study examines the views of patients with early-stage melanoma on the acceptability of the test and early treatment. Methods: A qualitative cross-sectional design using one-to-one semi-structured telephone interviews was employed. Twenty-five patients diagnosed with early-stage melanoma (Stage IA-IIC) were asked for their views on ctDNA monitoring and early treatment for relapse. Interviews were analysed using reflexive thematic analysis. Results: Two themes were generated: ctDNA monitoring would add service value where participants described regular ctDNA monitoring in follow-up care as more reassuring, more ""scientific"" than skin checks and preferable to scans. Test results provide opportunity and knowledge focuses on how participants wanted to know when to expect results to manage anxiety, with a positive result seen as an opportunity to receive treatment early. Conclusions: Participants were positive about ctDNA monitoring and early treatment and would welcome extra surveillance, as well as trust ctDNA tests. This indicates the feasibility of the wider implementation of ctDNA tests, which have applicability for many tumour types and disease stages."en_US
dc.language.isoenen_US
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-022-01766-xen_US
dc.titleCirculating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanomaen_US
dc.typeArticleen_US
dc.contributor.departmentManchester Centre of Health Psychology, Division of Psychology & Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, Manchesteren_US
dc.identifier.journalBritish Journal of Canceren_US
refterms.dateFOA2022-06-28T10:23:07Z


Files in this item

Thumbnail
Name:
Woof.pdf
Size:
619.9Kb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record